Advances in the treatment of malignant pleural mesothelioma

Chest

Volumn 116, Issue 2, 1999, Pages 504-520

  Sterman, Daniel H ^a   Kaiser, Larry R ^a   Albelda, Steven M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chemotherapy; Extrapleural pneumonectomy; Gene therapy; Immunotherapy; Mesothelioma; Photodynamic therapy; Pleurectomy; Pleurodesis; Pneumonectomy; Radiation

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DETORUBICIN; DOCETAXEL; DOXORUBICIN; EDATREXATE; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 2; METHOTREXATE; MITOMYCIN; PACLITAXEL; TRANSFORMING GROWTH FACTOR BETA; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER SURVIVAL; EUROPE; GENE THERAPY; HUMAN; IMMUNOTHERAPY; LYMPHOKINE ACTIVATED KILLER CELL; MULTIMODALITY CANCER THERAPY; PHOTODYNAMIC THERAPY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; UNITED STATES;

EID: 0032782922     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.116.2.504     Document Type: Article

References (146)

1. Robinson LA, Reilly RB. Localized pleural mesothelioma: the clinical spectrum. Chest 1994; 106:1611-1615
2. Obers VJ, Leiman G, Girdwood RW, et al. Primary malignant pleural tumors (mesotheliomas) presenting as localized masses: fine needle aspiration cytologic findings, clinical and radiologic features and review of the literature. Acta Cytol 1988; 32:567-575
3. Brenner J, Sordillo PP, Magill GB, et al. Malignant mesothelioma of the pleura: review of 123 patients. Cancer 1982; 49:2431-2435
4. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996; 111:815-825
5. Huncharek M, Kelsey K, Mark EJ, et al. Treatment and survival in diffuse malignant pleural mesothelioma: a study of 83 cases from the Massachusetts General Hospital. Anticancer Res 1996; 16:1265-1268
6. Falkson G, Alberts AS, Falkson HC. Malignant pleural mesothelioma treatment: the current state of the art. Cancer Treat Rev 1988; 15:231-242
7. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 16:527-535
8. Harvey JC, Erdman C, Pisch J, et al. Diffuse malignant pleural mesothelioma: options in surgical treatment. Compr Ther 1995; 21:13-19
9. Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Ann Intern Med 1982; 96:746-755
10. Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol 1981; 8:313-320
11. Harvey JC, Fleischman EH, Kagan AR, et al. Malignant pleural mesothelioma: A survival study. J Surg Oncol 1990; 45:40-42
12. Law MR, Hodson ME, Turner-Warwick M. Malignant mesothelioma of the pleura: Clinical aspects and symptomatic treatment. Eur J Respir Dis 1984; 65:162-168
13. Chailleux E, Dabouis G, Pioche D, et al. Prognostic factors in diffuse malignant pleural mesothelioma: A study of 167 patients. Chest 1988; 93:159-162
14. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients. J Clin Oncol 1989; 7:1157-1168
15. Ryan CW, Hemdon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998; 113(suppl):66S-73S
16. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma [review]: a review. J Clin Oncol 1996; 14:1007-1017
17. Solheim OP, Saeter G, Finnanger AM, et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: A phase II study. Br J Cancer 1992; 65:956-960
18. Harvey VJ, Slevin ML, Ponder BA, et al. Chemotherapy of diffuse malignant mesothelioma: Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 1984; 54:961-964
19. Vogelzang NJ, Schultz SM, Iannucci AM, et al. Malignant mesothelioma: The University of Minnesota experience. Cancer 1984; 53:377-383
20. Lerner HJ, Schoenfeld DA, Martin A, et al. Malignant mesothehoma: The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983; 52:1981-1985
21. Rossof AH. Treatment II: chemotherapy in the management of malignant mesothelioma. In: Kittle CF, ed. Mesothelioma: Diagnosis and Management. Chicago, IL: Year Book Medical Publishers, 1987; 73-78
22. Moreno de la Santa P, Butchart EG. Therapeutic options in malignant mesothelioma. Curr Opin Oncol 1995; 7:134-137
23. Planting AS, van der Burg ME, Goey SH, et al. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann Oncol 1995; 6:613-615
24. Raghavan D, Gianoutsos P, Bishop J, et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990; 8:151-154
25. Vogelzang NJ, Goutsou M, Corson JM, et al. Carboplatin in malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990; 27:239-242
26. Zidar BL, Green S, Pierce HI, et al. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study. Invest New Drugs 1988; 6:223-226
27. Mbidde EK, Harland SJ, Calvert AH, et al. Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 1986; 18:284-285
28. Martensson G, Sorenson S. A phase II study of vincristine in malignant mesothelioma: A negative report. Cancer Chemother Pharmacol 1989; 24:133-134
29. Bajorin D, Kelsen D, Mintzer DM. Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 1987; 71:857-858
30. Magri MD, Foladore S, Veronesi A, et al. Treatment of malignant mesothelioma with epirubicin and ifostamide: A phase II cooperative study. Ann Oncol 1992; 3:237-238
31. Alberts AS, Falkson G, Van Zyl L. Malignant pleural mesothelioma: Phase II pilot study of ifosfamide and mesna [letter]. J Natl Cancer Inst 1988; 80:698-700
32. Herscher LL, Hahn SM, Kroog G, et al. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small cell lung cancer. J Clin Oncol 1998; 16:635-641
33. Palackdharry CS. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: Preliminary results. Semin Oncol 1996; 23:78-83
34. van Meerbeeck J, Debruyne C, van Zandwijk N, et al. Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996; 74:961-963
35. Bischoff HG, Manegold C, Knopp M, et al. Gemcitabine may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma [abstract]. Paper presented at the 34th Annual Meeting of the American Society of Clinical Oncology; May 16-19, 1998; Los Angeles, CA
36. Costanzi J, Darzynkiewicz Z, Chun H, et al. The use of Onconase for patients with advanced malignant mesothelioma [abstract]. Paper presented at the 32nd Annual Meeting of the American Society of Clinical Oncology, Philadelphia, PA, 1996
37. Hunt KJ, Longton G, Williams MA, et al. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy. Chest 1996; 109:1239-1242
38. Hasturk S, Tastepe I, Unlu M, et al. Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients. J Chemother 1996; 8:159-164
39. Anand A, Anand A, Anand N. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma [letter]. Cancer 1996; 77:1959-1960
40. Shin DM, Fossella FV, Umsawasdi T, et al. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 1995; 76:2230-2236
41. Dirix LY, van Meerbeeek J, Schrijvers D, et al. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 1994; 5:653-655
42. Tsavaris N, Mylonakis N, Karvounis N, et al. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer 1994; 11:299-303
43. Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993; 11:1559-1565
44. Gridelli C, Pepe R, Airoma G, et al. Mitomycin C and vindesine: An ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma. Tumori 1992; 78:380-382
45. Ardizzoni A, Rosso R, Salvati F, et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma: An Italian Lung Cancer Task Force (FONICAP) phase II study. Cancer 1991; 67:2984-2987
46. Antman KH, Pass HI, Li FP, et al. Benign and malignant mesothelioma. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 4th Ed. Philadelphia, PA: JB Lippincott, 1993; 1489-1508
47. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1995; 107:332S-344S
48. Krarup-Hansen A, Hansen HH. Chemotherapy in malignant mesothelioma: A review. Cancer Chemother Pharmacol 1991; 28:319-330
49. Byrne ME, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study [abstract]. Paper presented at the 34th Annual Meeting of the American Society of Clinical Oncology; May 16-19, 1998; Los Angeles, CA
50. Colleoni M, Sartori F, Calabro F, et al. Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. Tumori 1996; 82:53-56
51. Sauter ER, Langer C, Coia LR, et al. Optimal management of malignant mesothelioma after subtotal pleurectomy: Revisiting the role of intrapleural chemotherapy and postoperative radiation. J Surg Oncol 1995; 60:100-105
52. Figlin R, Mendoza E, Piantadosi S, et al. Intrapleural chemotherapy without pleurodesis for malignant pleural effusions: LCSG Trial 861. Chest 1994; 106(suppl):363S-366S
53. Lerza R, Esposito M, Vannozzi M, et al. High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma: Clinical observations and pharmacokinetic analyses. Cancer 1994; 73:79-84
54. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992; 118:547-550
55. Davis SR, Tan L, Ball DL. Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation. Australas Radiol 1994; 38:212-214
56. Reddy S. Treatment III: radiation in the therapy of malignant mesothelioma. In: Kittle CF, ed. Mesothelioma: Diagnosis and Management. Chicago, IL: Year Book Medical Publishers, 1987; 79-86
57. Maasilta P, Kivisaari L, Holsti LR, et al. Radiographic chest assessment of lung injury following hemithorax irradiation for pleural mesothelioma. Eur Respir J 1991; 4:76-83
58. Hilaris BS, Nori D, Kwong E, et al. Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 1984; 10:325-331
59. Mattson K, Holsti LR, Tammilehto, L, et al. Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation. Int J Radiat Oncol Biol Phys 1992; 24:643-650
60. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: A randomized trial of local radiotherapy. Chest 1995; 108:754-758
61. Vogelzang NJ. Malignant mesothelioma: Diagnostic and management strategies for 1992. Semin Oncol 1992; 19:64-71
62. Pass HI, Pogrebniak HW. Malignant pleural mesothelioma. Curr Probl Surg 1993; 30:921-1012
63. Patz EF Jr, Shaffer K, Piwnica-Worms DR, et al. Malignant pleural mesothelioma: Value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol 1992; 159:961-966
64. Bénard F, Sterman DH, Smith RJ, et al. Metabolic imaging of malignant pleural mesothelioma with fluorine-18-deoxyglucose positron emission tomography. Chest 1998; 114:713-722
65. Kittle CF. Treatment I: The surgical treatment of mesothelioma. In: Kittle CF, ed. Mesothelioma: Diagnosis and Management. Chicago, IL: Year Book Medical Publishers, 1987; 61-72
66. Pass HI, Kranda K, Temeck BK, et al. Surgically debulked malignant pleural mesothelioma: Results and prognostic factors. Ann Surg Oncol 1997; 4:215-222
67. Aisner J. Therapeutic approach to malignant mesothelioma. Chest 1989; 96(suppl):95S-97S
68. Brancatisano RP, Joseph MG, McCaughan BC. Pleurectomy for mesothelioma. Med J Aust 1991; 154:455-457, 460
69. Sugarbaker DJ, Jaklitsch MT, Soutter AD, et al. Multimodality therapy of malignant mesothelioma. In: Roth JA, Ruckdeschel JC, Weisenburger TH, eds. Thoracic Oncology. 2nd Ed. Philadelphia, PA: WB Saunders, 1995; 538-555
70. Sugarbaker DJ, Heher EC, Lee TH, et al. Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991; 102:10-14
71. Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: Experience with 29 patients. Thorax 1976; 31:15-24
72. Faber LP. Extrapleural pneumonectomy for diffuse, malignant mesothelioma. Ann Thorac Surg 1994; 58:1782-1783
73. Allen KB, Faber LP, Warren WH. Malignant pleural mesothelioma: Extrapleural pneumonectomy and pleurectomy. Chest Surg Clin North Am 1994; 4:113-126
74. Faber LP. Surgical treatment of asbestos-related disease of the chest. Surg Clin North Am 1988; 68:525-543
75. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma: A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991; 102:1-9
76. Rusch VW. Trials in malignant mesothelioma: LCSG 851 and 882. Chest 1994; 106(suppl):359S-362S
77. Rusch VW. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest 1993; 103(suppl):382S-384S
78. Harpole DH, Liptay MJ, DeCamp MM Jr, et al. Prospective analysis of pneumonectomy: Risk factors for major morbidity and cardiac dysrhythmias. Ann Thorac Surg 1996; 61:977-982
79. Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: Who benefits? Chest 1995; 107(suppl):345S-350S
80. Keller SM. Adjuvant therapy for malignant pleural mesothelioma [review]. Chest Surg Clin North Am 1994; 4:127-135
81. Linden CJ, Mercke C, Albrechtsson U, et al. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: A nonrandomized phase II study. Eur Respir J 1996; 9:2565-2572
82. Sinoff C, Falkson G, Sandison AG, et al. Combined doxorubicin and radiation therapy in malignant pleural mesothelioma. Cancer Treat Rep 1982; 66:1605-1607
83. Sugarbaker DJ, Norberto JJ. Multimodality management of malignant pleural mesothelioma. Chest 1998; 113(suppl):61S-65S
84. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997; 63:334-338
85. Sugarbaker DJ, Mentzer SJ, DeCamp M, et al. Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma. Chest 1993; 103(suppl):377S-381S
86. Calavrezos A, Koschel G, Husselmann H, et al. Malignant mesothelioma of the pleura: A prospective therapeutic study of 132 patients from 1981-1985. Klin Wochenschr 1988:66:607-613
87. Martini N, McCormack PM, Bains MS, et al. Pleural mesothelioma. Ann Thorac Surg 1987; 43:113-120
88. Rusch VW, Figlin R, Godwin D, et al. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: A Lung Cancer Study Group trial. J Clin Oncol 1991; 9:313-319
89. Lee JD, Perez S, Wang HJ, et al. Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: The UCLA experience. J Surg Oncol 1995; 60:262-267
90. Middleton GW, Smith IE, O'Brien MER, et al. Good symptom relief with palliative MVP (mitomicin C, vinblastine, cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998; 9:269-273
91. Hartman DL, Gaither JM, Kesler KA, et al. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 1993; 105:743-747
92. Tsang V, Fernando HC, Goldstraw P. Pleuroperitoneal shunt for recurrent malignant pleural effusions. Thorax 1990; 45:369-372
93. Prior AJ, Ball AB. Intestinal obstruction complicating malignant mesothelioma of the pleura. Respir Med 1993; 87:147-148
94. Pass HI, Donington JS. Use of photodynamic therapy for the management of pleural malignancies. Semin Surg Oncol 1995; 11:360-367
95. Henderson BW, Dougherty TJ. Photodynamic Therapy: Basic Principles and Clinical Applications. New York, NY: Marcel Dekker, 1992
96. Koren H, Schenk GM, Jindra RH, et al. Hypericin in phototherapy. J Photochem Photobiol B 1996; 36:113-119
97. Ris HB, Altermatt HJ, Nachbur B, et al. Intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin for chest malignancies. Lasers Surg Med 1996; 18:39-45
98. Pass HI, Temeck BK, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997; 4:628-633
99. Takita H, Mang TS, Loewen GM, et al. Operation and intracavitary photodynamic therapy for malignant pleural mesothehoma: A phase II study. Ann Thorac Surg 1994; 58:995-998
100. Temeck BK, Pass HI. Esophagopleural fistula: A complication of photodynamic therapy. South Med J 1995; 88:271-274
101. Luketich JD, Westkaemper J, Sommers KE, et al. Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma. Ann Thorac Surg 1996; 62:283-284
102. Baas P, Murrer L, Zoetmulder F, et al. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer 1997; 78:819-826
103. Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 1995; 12:455-460
104. Jarnicki AG, Fitzpatrick DR, Robinson BW, et al. Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma. Cancer Lett 1996; 103:1-9
105. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, et al. Transforming growth factor-beta: Antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994; 11:29-44
106. Lew F, Tsang P, Holland JF, et al. High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma. J Clin Immunol 1986; 6:225-233
107. Kagan E. The alveolar macrophage: Immune derangement and asbestos-related malignancy. Semin Oncol 1981; 8:258-267
108. Henderson DW, Attwood HD, Constance TJ, et al. Lymphohistiocytoid mesothelioma: A rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. Ultrastruct Pathol 1988; 12:367-384
109. Christmas TI, Manning LS, Garlepp MJ, et al. Effect of interferon-alpha 2a on malignant mesothelioma. J Interferon Res 1993; 13:9-12
110. Astoul P, Viallat JR, Laurent JC, et al. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 1993; 103:209-213
111. Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994; 74:2460-2467
112. Boutin C, Viallat JR, Van Zandwijk N, et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 1991; 67:2033-2037
113. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, et al. Potential for interferon-alpha-based therapy in mesothelioma: Assessment in a murine model. J Interferon Cytokine Res 1995; 15:213-223
114. Ardizzoni A, Pennucci MC, Castagneto B, et al. Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am J Clin Oncol 1994; 17:80-82
115. Von Hoff DD, Metch B, Lucas JG, et al. Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: A Southwest Oncology Group study. J Interferon Res 1990; 10:531-534
116. Rosso R, Rimoldi R, Salvati F, et al. Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 1988; 45:253-256
117. Robinson BWS, Bowman RV, Manning LS, et al. Interleukin-2 and lymphokine-activated killer cells in malignant mesothelioma. Eur Respir Rev 1993; 3:220-222
118. Goey SH, Eggermont AM, Punt CJ, et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: A phase I-II study. Br J Cancer 1995; 72:1283-1288
119. Castagneto B, Degiovanni D, Mutt L, et al. Intracavitary and systemic rIL-2 in the treatment of malignant pleural mesothelioma. Paper presented at the International Mesothelioma Interest Group Conference; 1997; Philadelphia, PA
120. Astoul P, Picat-Joossen D, Viallat JR, et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: A phase II study. Cancer 1998; 83:2099-2104
121. Lopez M, Chokri M, Monne I, et al. Local adoptive immunotherapy using interferon gamma-activated autologous macrophages in malignant pleural mesothelioma [abstract]. Paper presented at the Sixth International Conference on Anticancer Treatment, Paris, France, 1996
122. Robinson BW, Mukherjee SA, Davidson A, et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 1998; 21:211-217
123. Jaurand MC, Barrett JC. Neoplastic transformation of mesothelial cells. In: Jaurand M-C, Bignon J, eds. The Mesothelial Cell and Mesothelioma. New York, NY: Marcel Dekker, 1994; 207-221
124. Soulie P, Ruffie P, Trandafir L, et al. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma: Report of a phase I-II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol 1996; 14:878-885
125. Pass HW, Temeck BK, Kranda K, et al. A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann Surg Oncol 1995; 2:214-220
126. Upham JW, Musk AW, van Hazel G, et al. Interferon alpha and doxorubicin in malignant mesothelioma: A phase II study. Aust NZ J Med 1993; 23:683-687
127. Tiberghien P. Use of suicide genes in gene therapy. J Leukoc Biol 1994; 56:203-209
128. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 1988; 10(suppl):S490-S494
129. Elshami A, Saavedra A, Zhang H, et al. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996; 3:85-92
130. Pope IM, Poston GJ, Kinsella AR. The role of the bystander effect in suicide gene therapy. Eur J Cancer 1997; 33:1005-1016
131. Smythe WR, Kaiser LR, Hwang HC, et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 1994; 57:1395-1401
132. Smythe WR, Hwang HC, Amin KM, et al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: An effective in vitro drug sensitization system. Cancer Res 1994; 54:2055-2059
133. Esandi MC, van Someren GD, Vincent AJ, et al. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Ther 1997; 4:280-287
134. Hwang HC, Smythe WR, Elshami AA, et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995; 13:7-16
135. Smythe WR, Hwang HC, Elshami AA, et al. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995; 222:78-86
136. Treat J, Kaiser LR, Sterman DH, et al. Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: A phase 1 trial (BB-IND 6274). Hum Gene Ther 1996; 7:2047-2057
137. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase gene delivery in patients with localized malignancy: Results of a phase 1 clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9:1083-1092
138. Molnar-Kimber KL, Sterman DH, Chang M, et al. Humoral and cellular immune responses induced by adenoviral-based gene therapy for localized malignancy: Results of a phase 1 clinical trial for malignant mesothelioma. Hum Gene Ther 1998; 9:2121-2133
139. Davidson A, Morey S, Musk A, et al. Gene therapy or therapy by intratumoral cytokines by infusion in mesothelioma patients. Lung Cancer 1997; 18(suppl 2):94
140. Mukherjee S, Haenel T, Epton M, et al. Intralesional vaccinia virus-interleukin-2 (VV-IL-2) gene therapy in malignant mesothelioma (MM). Lung Cancer 1997; 18(suppl 1):236
141. Lukacs KV, Oakley RE, Pardo OE, et al. Gene therapy for malignant mesothelioma with a heat shock protein gene [abstract]. Am J Respir Crit Care Med 1998; 157:A741
142. Schwarzenberger P, Harrison L, Weinacker A, et al. Gene therapy for malignant mesothelioma: A novel approach for an incurable cancer with increased incidence in Louisiana. J La State Med Soc 1998; 150:168-174
143. Kolls J, Freeman S, Ramesh R, et al. The treatment of malignant pleural mesothelioma with gene modified cancer cells: A Phase I study [abstract]. Am J Respir Crit Care Med 1998; 157:A563
144. Schwarzenberger P, Lei D, Freeman SM, et al. Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma. Am J Respir Cell Mol Biol 1998; 19:333-337
145. Russell S. Replicating vectors for gene therapy of cancer: Risks, limitations and prospects. Eur J Cancer 1994; 30A:1165-1175
146. Kucharczuk JC, Randazzo B, Chang MY, et al. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res 1997; 57:466-471